Trial Profile

A phase II trial of CHOP-14 with Mogamulizumab for untreated elderly patients with CCR4 positive adult T-cell leukemia/lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 16 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mogamulizumab (Primary) ; Cyclophosphamide; Daunorubicin; Prednisolone; Vincristine
Indications Adult T-cell leukaemia-lymphoma
Focus Therapeutic Use
Acronyms Moga-CHOP-14

Most Recent Events

06 Jun 2023 Primary endpoint (1 year progression free survival) has been met, according to a results presented at the 59th Annual Meeting of the American Society of Clinical.
06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical .
22 Aug 2022 Planned End Date changed from 31 Oct 2021 to 31 Oct 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com